Costo – Efectividad De Apixaban Con Otros Noacs (Dabigatran Y Rivaroxaban) En El Tratamiento De La Fibrilacion Auricular No Valvular (Fanv) En Pacientes De La Seguridad Social De Perú

Abstract

A829Generalized linear regression models were used to examine associations between the total cost of hospitalization and various sociodemographic and clinical variables. Results: 301 patients were included; age 75.3 ± 11.8 years; 37% female; 57% with depressed ejection fraction; 46% of coronary artery disease. The blood pressure on admission was 129.8 ± 29.7 mmHg; renal function 26.2 ± 57.9 ml / min / 1.73 m2. In-hospital mortality was 7%. The length of stay was 7.82 ± 7.06 days (median 5.69), more prolonged in patients with renal impairment (8.59 vs. 8.18; p = 0.0329) and shorter in those with elevated blood pressure on admission (6.08 ± 4.03; p = 0.009). The average cost per patient was AR $ 68,861 ± 96,066 (US $ 8,071 ± 11,259; US $ 1 = AR $ 8.7928); 71% attributable to hospital stay, 20% for therapeutic procedures (mainly aortic valve surgery, implanted defibrillator and coronary angioplasty) and 6.7% for diagnostic studies (mainly radiology, laboratory and echocardiogram). In multivariate analysis, depressed ejection fraction, valve antecedent and impaired renal function at admission were associated with higher costs. ConClusions: Resource use and costs associated hospitalizations for heart failure are high, and the highest proportion is attributable to the costs of hospital stay.

Effects of dabigatran regulates no‑reflow phenomenon in acute myocardial infarction mice through anti‑inflammatory and anti‑oxidative activities and connective tissue growth factor expression

“…In October 2010, it was approved by Food and Drug Administration to be employed to prevent cerebral apoplexy for patients with auricular fibrillation (7). Pradaxa is effective to reduce risks of patients with atrial fibrillation (8). In addition, it can avoid the reinforcement of intracranial hemorrhage (9).…”